CBLL
CeriBell, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +8.4% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.84M | — | $90.63M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 1.52M | — | $28.46M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | The Vanguard Group ✦ (passive) | 1.33M | — | $24.85M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Millennium Management ✦ | 470.15K | +24.7% | $8.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 447.94K | +55.4% | $8.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 384.35K | +76.0% | $7.20M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 164.64K | New | $3.08M | 0.0% | New | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 76.17K | New | $1.43M | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Point72 Asset Management ✦ | 66.43K | New | $1.24M | 0.0% | New | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 44.14K | +41.4% | $826,798 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 12.47K | New | $234,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $3.08M | 0.0% |
| Citadel Advisors | $1.43M | 0.0% |
| Point72 Asset Management | $1.24M | 0.0% |
| T. Rowe Price | $234,000 | 0.0% |
Exited
| Soros Fund Management | $487,089 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 121 holders, 29.58M shares, $536.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.89K sh · $119,145
Officer, Director · 20.85K sh · $521,775
Officer · 846 sh · $21,150
Officer · 7.50K sh · $181,875
Officer · 1.75K sh · $42,576
Officer · 4.89K sh · $118,901
Officer · 652 sh · $16,300
Officer, Director · 39.54K sh · $973,079
Officer · 859 sh · $20,573
Officer, Director · 6.07K sh · $145,753
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology